In Silico Screening of Drugs That Target Different Forms of E Protein for Potential Treatment of COVID-19

Abstract

Recently the E protein of SARS-CoV-2 has become a very important target in the potential treatment of COVID-19 since it is known to regulate different stages of the viral cycle. There is biochemical evidence that E protein exists in two forms, as monomer and homopentamer. An in silico screening analysis was carried out employing 5852 ligands (from Zinc databases), and performing an ADMET analysis, remaining a set of 2155 compounds. Furthermore, docking analysis was performed on specific sites and different forms of the E protein. From this study we could identify that the following ligands showed the highest binding affinity: nilotinib, dutasteride, irinotecan, saquinavir and alectinib. We carried out some molecular dynamics simulations and free energy MM–PBSA calculations of the protein–ligand complexes (with the mentioned ligands). Of worthy interest is that saquinavir, nilotinib and alectinib are also considered as a promising multitarget ligand because it seems to inhibit three targets, which play an important role in the viral cycle. On the other side, saquinavir was shown to be able to bind to E protein both in its monomeric as well as pentameric forms. Finally, further experimental assays are needed to probe our hypothesis derived from in silico studies.

Metabolomic Profiling of Leptadenia reticulata: Unveiling Therapeutic Potential for Inflammatory Diseases through Network Pharmacology and Docking Studies

“…Network pharmacology maps interactions within biological networks, highlighting potential drug targets [ 21 ]. Molecular docking identifies promising ligand–receptor interactions, which are then refined through molecular dynamics simulations to assess the stability and dynamics of these complexes in a realistic environment [ 22 ]. This comprehensive framework enhances our understanding of molecular mechanisms and drug action, offering a robust strategy for drug discovery and development, with potential applications in personalized medicine and disease treatment.…”

β-Secretase-1: In Silico Drug Reposition for Alzheimer’s Disease

“…Verubecestat and EJ7, however, are still experimental drugs, and not feasible options for clinical application [19,33,34]. A new approach that has taken great advantage in the case of SARS-CoV-2019 is drug repositioning [35], where drug databases are used to locate second options for medical application with minimal or no side effects [36,37]. A database with wide application in the United States and Latin America is Drugbank [38] with which, through in silico studies, the repositioning of the drug is proposed in this work, which is associated with BACE-1 inhibitors.…”